Medical Device Network on MSN10h
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...
The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art ...
Early surgical or transcatheter aortic valve replacement is not typically recommended for severe aortic stenosis in the ...
In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to ...
Zacks Investment Research on MSN8h
Positive Trial Data on Evolut TAVR Likely to Support MDT StockMedtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.
The following is a summary of "Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated ...
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
Capstan CEO Maggie Nixon discusses first-in-human feedback, the all-at-once approach, regulatory strategy and the tricuspid ...
"Today marks a pivotal moment in the evolution of structural heart therapy," Capstan Medical CEO Maggie Nixon said.
The money will support an ongoing pivotal trial of 4C Medical Technologies' transcatheter mitral valve replacement device in ...
Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback